Merck Gets PTAB To Nix Pfizer Vaccine Patent

Law360 (March 13, 2019, 4:47 PM EDT) -- The Patent Trial and Appeal Board on Wednesday invalidated every claim of a Pfizer patent tied to next generation pneumonia vaccines, handing a win to rival Merck Sharp & Dohme Corp., which persuaded the board to ax a patent for a different pneumonia vaccine last year.

In a series of four final written decisions in inter partes reviews addressing different claims and invalidity arguments about the patent, the board found that Merck had shown that all 45 claims are invalid as obvious. It also rejected Pfizer's motion to amend the claims.

Merck also challenged another patent related to Prevnar 13 —...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!